The company could finally be ready to deliver on years of promise.

As the world races toward 10 billion people, farming is being reinvented by machines, data, and biology, from robotic ...

But CRISPR is a long-term story that is still in the early innings. The company has moved past its proof-of-concept phase, ...

Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to ...

Fulcrum® tools to support AI-driven crop trait developmentDurham, North Carolina and Oxford, United Kingdom, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pairwise, a global innovator in agriculture, today ...

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.

CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.

Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR ...

A new Crispr-powered optical blood test detects lung cancer biomarkers at sub-attomolar levels, offering earlier molecular detection than conventional PCR or imaging.